The Role of Type I Interferon Subtypes and Interferon-Gamma in Type I Interferon Diabetes Inhibitory Activity in the NOD Mouse

2016 ◽  
Vol 36 (4) ◽  
pp. 238-246 ◽  
Author(s):  
Douglas Sobel ◽  
Behrouz Ahvazi ◽  
Carol Pontzer
Keyword(s):  
Interferon Gamma ◽  
Inhibitory Activity ◽  
Type I Interferon ◽  
Nod Mouse ◽  
Type I

scholarly journals The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities

2021 ◽  
Vol 1 (1) ◽  
pp. 49-59
Author(s):  
Selvakumar Subbian
Keyword(s):  
Infectious Diseases ◽  
Disease Severity ◽  
Type I Interferon ◽  
Host Factors ◽  
Type I ◽  
The Novel ◽  
Inflammatory Drugs ◽  
Precautionary Measures ◽  
Inducible Genes

The Coronavirus Disease-2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has claimed 1.2 million people globally since December 2019. Although the host factors underpinning COVID-19 pathology are not fully understood, type I interferon (IFN-I) response is considered crucial for SARS-CoV-2 pathogenesis. Perturbations in IFN-I signaling and associated interferon-inducible genes (ISG) are among the primary disease severity indicators in COVID-19. Consequently, IFN-I therapy, either alone or in- combination with existing antiviral or anti-inflammatory drugs, is tested in many ongoing clinical trials to reduce COVID-19 mortality. Since signaling by the IFN-I family of molecules regulates host immune response to other infectious and non-infectious diseases, any imbalance in this family of cytokines would impact the clinical outcome of COVID-19, as well as other co-existing diseases. Therefore, it is imperative to evaluate the beneficial-versus-detrimental effects of IFN-I immunotherapy for COVID-19 patients with divergent disease severity and other co-existing conditions. This review article summarizes the role of IFN-I signaling in infectious and non-infectious diseases of humans. It highlights the precautionary measures to be considered before administering IFN-I to COVID-19 patients having other co-existing disorders. Finally, suggestions are proposed to improve IFN-I immunotherapy to COVID-19.

scholarly journals The Role of Optineurin in Antiviral Type I Interferon Production

2018 ◽  
Vol 9 ◽  
Author(s):  
Ahmed Outlioua ◽  
Marie Pourcelot ◽  
Damien Arnoult
Keyword(s):  
Type I Interferon ◽  
Type I ◽  
Interferon Production

scholarly journals STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral Control

2015 ◽  
Vol 11 (8) ◽  
pp. e1005084 ◽  
Author(s):  
Karoly Toth ◽  
Sang R. Lee ◽  
Baoling Ying ◽  
Jacqueline F. Spencer ◽  
Ann E. Tollefson ◽  
...  
Keyword(s):  
Type I Interferon ◽  
Human Adenovirus ◽  
Interferon Response ◽  
Type I ◽  
Viral Control ◽  
Syrian Hamsters

scholarly journals Role of Type I Interferon Receptor Signaling on NK Cell Development and Functions

PLoS ONE ◽  
2014 ◽  
Vol 9 (10) ◽  
pp. e111302 ◽  
Author(s):  
Jean Guan ◽  
S. M. Shahjahan Miah ◽  
Zachary S. Wilson ◽  
Timothy K. Erick ◽  
Cindy Banh ◽  
...  
Keyword(s):  
Nk Cell ◽  
Type I Interferon ◽  
Cell Development ◽  
Type I ◽  
Receptor Signaling ◽  
Interferon Receptor

Role of Leptin and SOCS3 in Inhibiting the Type I Interferon Response During Obesity

Inflammation ◽  
2016 ◽  
Vol 40 (1) ◽  
pp. 58-67 ◽  
Author(s):  
Elí Terán-Cabanillas ◽  
Jesús Hernández
Keyword(s):  
Type I Interferon ◽  
Interferon Response ◽  
Type I
Sign in / Sign up

Export Citation Format

Share Document